Detection of residual or recurrent vital renal tumor on follow-up (FU) cross-sectional imaging after ablative therapy is challenging. The specific and high expression levels of carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma (ccRCC) makes it a suitable target for imaging using radiolabeled anti-CAIX antibody girentuximab. The objective of this study was to evaluate the feasibility of targeted FU imaging 1 month after cryoablation of ccRCC using single photon emission computed tomography (SPECT) after ¹¹¹In-labeled girentuximab administration.

中文翻译：

---

冷冻消融透明细胞肾细胞癌后的后续成像是可行的，可以使用111In-girentuximab的单光子发射计算机断层扫描。

消融治疗后通过随访（FU）断层成像检测残余或复发性重要肾肿瘤具有挑战性。碳酸酐酶IX（CAIX）在透明细胞肾细胞癌（ccRCC）中的特异性和高表达水平使其成为使用放射性标记的抗CAIX抗体girentuximab进行成像的合适靶标。这项研究的目的是评估¹¹¹ In-In-girentuximab给药后使用单光子发射计算机断层扫描（SPECT）对ccRCC冷冻消融后1个月进行靶向FU成像的可行性。